Cargando…
Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study
Lung adenocarcinoma (LUAD) is a non-small-cell lung cancer and is the leading cause of cancer-related deaths worldwide. Immunotherapy is a promising candidate for LUAD, and tumor mutation burden (TMB) could be a new biomarker to monitor the response of cancer patients to immunotherapy. It is known t...
Autores principales: | Liu, Tingjun, Wu, Lianlian, Liu, Jing, Chen, Hao, Zhu, Bao, Qiao, Dandan, Zhu, Yuhua, Liu, Tingya, Chen, Quangang, Hu, Ankang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627637/ https://www.ncbi.nlm.nih.gov/pubmed/37932988 http://dx.doi.org/10.1097/MD.0000000000035481 |
Ejemplares similares
-
Comprehensive analysis identifies DNA damage repair-related gene HCLS1 associated with good prognosis in lung adenocarcinoma
por: Liu, Tingjun, et al.
Publicado: (2023) -
In silico analysis reveals PRR11 as a prognostic and oncogenic marker in lung adenocarcinoma
por: Hu, Ankang, et al.
Publicado: (2023) -
Prognosis-related autophagy genes in female lung adenocarcinoma
por: Liu, Zhongxiang, et al.
Publicado: (2022) -
Construction of an m6A-related lncRNA model for predicting prognosis and immunotherapy in patients with lung adenocarcinoma
por: Shen, Hong-Yu, et al.
Publicado: (2023) -
Discovery of rafoxanide as a novel agent for the treatment of non-small cell lung cancer
por: Hu, Ankang, et al.
Publicado: (2023)